Skip to main navigation Skip to search Skip to main content

Detection of copy number variations in epilepsy using exome data

  • N. Tsuchida
  • , M. Nakashima
  • , M. Kato
  • , E. Heyman
  • , T. Inui
  • , K. Haginoya
  • , S. Watanabe
  • , T. Chiyonobu
  • , M. Morimoto
  • , M. Ohta
  • , A. Kumakura
  • , M. Kubota
  • , Y. Kumagai
  • , S. I. Hamano
  • , C. M. Lourenco
  • , N. A. Yahaya
  • , G. S. Ch'ng
  • , L. H. Ngu
  • , A. Fattal-Valevski
  • , M. Weisz Hubshman
  • N. Orenstein, D. Marom, L. Cohen, H. Goldberg-Stern, Y. Uchiyama, E. Imagawa, T. Mizuguchi, A. Takata, N. Miyake, H. Nakajima, H. Saitsu, S. Miyatake, N. Matsumoto
  • Yokohama City University
  • Hamamatsu University School of Medicine
  • Yamagata University
  • Showa Medical University
  • Assaf Harofeh Medical Center
  • Miyagi Children's Hospital
  • Kyoto Prefectural University of Medicine
  • JA Toride General Hospital
  • Tazuke Kofukai, Medical Research Institute, Kitano Hospital
  • National Center for Child Health and Development
  • Saitama Children's Medical Center
  • Universidade de São Paulo
  • Hospital Raja Perempuan Zainab II
  • Kuala Lumpur Hospital
  • Tel Aviv University
  • Tel Aviv Sourasky Medical Center
  • Schneider Childrens Medical Center Israel
  • Rabin Medical Center Israel

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Epilepsies are common neurological disorders and genetic factors contribute to their pathogenesis. Copy number variations (CNVs) are increasingly recognized as an important etiology of many human diseases including epilepsy. Whole-exome sequencing (WES) is becoming a standard tool for detecting pathogenic mutations and has recently been applied to detecting CNVs. Here, we analyzed 294 families with epilepsy using WES, and focused on 168 families with no causative single nucleotide variants in known epilepsy-associated genes to further validate CNVs using 2 different CNV detection tools using WES data. We confirmed 18 pathogenic CNVs, and 2 deletions and 2 duplications at chr15q11.2 of clinically unknown significance. Of note, we were able to identify small CNVs less than 10 kb in size, which might be difficult to detect by conventional microarray. We revealed 2 cases with pathogenic CNVs that one of the 2 CNV detection tools failed to find, suggesting that using different CNV tools is recommended to increase diagnostic yield. Considering a relatively high discovery rate of CNVs (18 out of 168 families, 10.7%) and successful detection of CNV with <10 kb in size, CNV detection by WES may be able to surrogate, or at least complement, conventional microarray analysis.

Original languageEnglish
Pages (from-to)577-587
Number of pages11
JournalClinical Genetics
Volume93
Issue number3
DOIs
StatePublished - Mar 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Funding

Technology Agency (JST); Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Japan Agency for Medical Research and Development (AMED); Strategic Research Program for Brain Science; Comprehensive Research on Disability Health and Welfare grant; Research on Measures for Intractable Diseases grant We would like to thank the patients and their families for their participation in this study. We are also grateful to Ms. Mai Sato, Ms. Nobuko Watanabe, Ms. Sayaka Sugimoto, Ms. Kaori Takabe, Mr. Syohei Nakamura, and Mr. Takafumi Miyama from Department of Human Genetics, Yokohama City University Graduate School of Medicine for their excellent technical assistance. This work is supported by the grants for Research on Measures for Intractable Diseases grant; the Comprehensive Research on Disability Health and Welfare grant; the Strategic Research Program for Brain Science; the Practical Research Project for Rare/Intractable Diseases, from the Japan Agency for Medical Research and Development (AMED); a grant-in-aid for Scientific Research on Innovative Areas (Transcription Cycle) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); grants-in-aid for Scientific Research (A, B and C); Challenging Exploratory Research and Young Scientists (B) from the Japan Society for the Promotion of Science (JSPS); the Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program in the Project for Developing Innovation Systems from the Japan Science and Technology Agency (JST); and grants from the Ministry of Health, Labor and Welfare and the Takeda Science Foundation. Wendy Brooks, PhD, from Edanz Group (www.edanzediting.com/ac) provided English language editing services for a draft of this manuscript.

FundersFunder number
Takeda Science Foundation
Japan Agency for Medical Research and Development
Japan Society for the Promotion of Science16H05160, 16H05357, 16K09975, 17K15630
Ministry of Education, Culture, Sports, Science and Technology
Japan Science and Technology Agency
Ministry of Health, Labour and Welfare

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • copy number variation
    • epilepsy
    • microdeletion
    • whole-exome sequencing

    Fingerprint

    Dive into the research topics of 'Detection of copy number variations in epilepsy using exome data'. Together they form a unique fingerprint.

    Cite this